Please use this identifier to cite or link to this item:
http://hdl.handle.net/1942/2873
Title: | Randomized designs for early trials of new cancer treatments - An overview | Authors: | BUYSE, Marc | Issue Date: | 2000 | Publisher: | DRUG INFORMATION ASSOCIATION | Source: | DRUG INFORMATION JOURNAL, 34(2). p. 387-396 | Abstract: | This paper argues that randomization should more often be considered for early trials of experimental cancer treatments. Uncontrolled as well as randomized designs for Phase II trials are reviewed The severe limitations of uncontrolled designs are illustrated, and possible difficulties with randomized designs discussed. It is argued that in randomized Phase II trials, the treatment allocation method should be chosen to achieve good balance with respect to the most important prognostic factors. | Notes: | Int Inst Drug Dev ID2, B-1050 Brussels, Belgium. Limburgs Univ Ctr, Diepenbeek, Belgium.Buyse, M, Int Inst Drug Dev ID2, 430 Ave Louise,B14, B-1050 Brussels, Belgium. | Keywords: | phase II trials; cancer treatments; randomization | Document URI: | http://hdl.handle.net/1942/2873 | ISI #: | 000087220200007 | Category: | A1 | Type: | Journal Contribution | Validations: | ecoom 2001 |
Appears in Collections: | Research publications |
Show full item record
Google ScholarTM
Check
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.